EMA recommends suspension of sickle cell disease medicine Oxbryta

View source ↗

Summary

EMA recommends suspending the sickle cell disease medicine Oxbryta (voxelotor) as a precaution while emerging data are reviewed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

Measure taken as precaution while review of emerging data is ongoing